-
Product Insights
NewPontine Glioma – Drugs In Development, 2024
Empower your strategies with our Pontine Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, drooping of one side of the face, and difficulty...
-
Product Insights
NewEndocrine Gland Disorders – Drugs In Development, 2024
Empower your strategies with our Endocrine Gland Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Endocrine gland disorders are medical conditions that affect the function of the endocrine system, which is a network of glands that produce and release hormones that regulate many body processes. Some common endocrine disorders are diabetes, hyperthyroidism, hypothyroidism, Cushing's disease, and polycystic ovary syndrome (PCOS). These disorders can result from various causes, such as tumors, genetic factors, hormonal imbalances, or autoimmune...
-
Product Insights
NewNon Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2024
Empower your strategies with our Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – Drugs In Development, 2024 report and make more profitable business decisions. Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Most people with NAFLD experience no signs and symptoms and no complications, but in some people with the disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are...
-
Product Insights
NewRecurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024
Empower your strategies with our Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent glioblastoma multiforme (GBM) refers to the return of aggressive brain tumors known as glioblastomas after initial treatment. GBM is the most malignant type of glioma, characterized by rapid growth and infiltrative behavior. Despite aggressive therapies like surgery, radiation, and chemotherapy, GBM often recurs due to its invasive nature and resistance to treatment. Management of recurrent GBM poses significant challenges....
-
Product Insights
NewBrain Cancer – Drugs In Development, 2024
Empower your strategies with our Brain Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Brain cancer refers to the abnormal growth of cells in the brain, forming tumors that can be benign (non-cancerous) or malignant (cancerous). Primary brain tumors originate in the brain itself, while secondary tumors result from the spread of cancer from other parts of the body. Symptoms may include headaches, seizures, changes in behavior, and cognitive impairment. Diagnosis involves imaging studies like MRI...
-
Product Insights
NewGrowth Disorders – Drugs In Development, 2024
Empower your strategies with our Growth Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Growth disorders are problems that prevent children from developing normal height, weight, sexual maturity or other features. Very slow or very fast growth can sometimes signal a gland problem or disease. The pituitary gland makes growth hormone, which stimulates the growth of bone and other tissues. Children who have too little of it may be very short. Treatment with growth hormone can...
-
Product Insights
NewIdiopathic Short Stature – Drugs In Development, 2024
Empower your strategies with our Idiopathic Short Stature – Drugs In Development, 2024 report and make more profitable business decisions. Idiopathic short stature is a condition in which the height of the individual is more than 2 standard deviations below the corresponding mean height for a given age, sex, and population, in whom no identifiable disorder is present. It can be subcategorized into familial and non-familial ISS, and according to pubertal delay. The Idiopathic Short Stature drugs in development market research...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Non Alcoholic Fatty Liver Disease (NAFLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Non Alcoholic Fatty Liver Disease (NAFLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Non Alcoholic Fatty Liver...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NUV-868 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NUV-868 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NUV-868 in Ovarian Cancer Drug Details:NUV-868 is under development for the treatment of...